Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Study’s final report confirms letrozole’s benefit for breast cancer patients

07.09.2005


Aromatase inhibitor improves survival for some patients, reduces metastasis

The complete analysis of data from an international trial of the drug letrozole (Femara) confirms earlier reports that the drug reduced the recurrence of breast cancer in women previously treated with tamoxifen. It also finds that letrozole prevents the development of metastases, even in women whose cancer had originally spread to their lymph nodes. The report appears in the September 7 issue of the Journal of the National Cancer Institute.

"The most important new findings we describe in this article are that letrozole treatment can improve the survival of women with node-positive disease and can reduce the chance that metastatic tumors will develop," says Paul E. Goss, MD, PhD, who led the investigation. At the study’s outset, Goss was with the Princess Margaret Hospital in Toronto; he now is director of Breast Cancer Research at Massachusetts General Hospital Cancer Center.



Letrozole is one of a class of drugs called aromatase inhibitors that suppress the production of estrogen. Estogen stimulates the growth of breast tumors that express the estrogen receptor, and drugs that block the production or the action of the hormone are used in the treatment of those tumors. The most widely used estrogen-blocking drug is tamoxifen, which becomes ineffective after five years of treatment, probably because tumor cells become resistant to or even dependent on the drug.

The international study, called the MA.17 trial, was conducted through the National Cancer Institute of Canada and designed to test whether letrozole could reduce tumor recurrence and increase survival in postmenopausal breast cancer patients who had completed five years of tamoxifen treatment. More than 5,000 women were enrolled and randomly assigned to receive either letrozole or a placebo for an additional five years. The study was halted in October 2003 – four years after it began – when an interim data analysis showed that the tumors of women taking letrozole were significantly less likely recur. Those results were published in the November 6, 2003 New England Journal of Medicine.

The current report analyzes all the data compiled during the MA.17 trial and confirms that the risk of recurrence was almost 5 percent lower in those receiving letrozole than in the placebo group. Women receiving the drug also had a 39 percent reduction in the risk of metastasis. While overall survival differences between the two groups were not significant, among women whose tumors had spread to their lymph nodes and those who had received tamoxifen for more than five years, letrozole was associated with significantly better overall survival.

Although participants taking letrozole did have a greater incidence of osteoporosis, there was no significant difference in reported fractures. There was also no increased risk of cardiovascular problems, which Goss says is particularly noteable. "A recent trial comparing letrozole to tamoxifen found that letrozole might be associated with heart problems. But our study, the only placebo-controlled trial of an aromatase inhibitor, found no such association. A possible explanation of the earlier study was that tamoxifen may actually protect against cardiovascular disease, which our results support."

Goss adds that current and future studies will investigate two key questions about letrozole and other aromatase inhibitors – how long treatment should continue and whether the drugs also can benefit women who previously stopped taking tamoxifen or never took that drug. One trial that has already begun will continue following the women who received letrozole throughout the MA.17 trial and re-randomize them to receive either letrozole or a placebo for an additional five years. Another study will examine tumor samples from all MA.17 trial participants to search for molecular fingerprints that might identify who would most benefit from letrozole treatment.

Emily Parker | EurekAlert!
Further information:
http://www.mgh.harvard.edu/

More articles from Studies and Analyses:

nachricht When a fish becomes fluid
17.12.2018 | Institute of Science and Technology Austria

nachricht Some brain tumors may respond to immunotherapy, new study suggests
11.12.2018 | Columbia University Irving Medical Center

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Data storage using individual molecules

Researchers from the University of Basel have reported a new method that allows the physical state of just a few atoms or molecules within a network to be controlled. It is based on the spontaneous self-organization of molecules into extensive networks with pores about one nanometer in size. In the journal ‘small’, the physicists reported on their investigations, which could be of particular importance for the development of new storage devices.

Around the world, researchers are attempting to shrink data storage devices to achieve as large a storage capacity in as small a space as possible. In almost...

Im Focus: Data use draining your battery? Tiny device to speed up memory while also saving power

The more objects we make "smart," from watches to entire buildings, the greater the need for these devices to store and retrieve massive amounts of data quickly without consuming too much power.

Millions of new memory cells could be part of a computer chip and provide that speed and energy savings, thanks to the discovery of a previously unobserved...

Im Focus: An energy-efficient way to stay warm: Sew high-tech heating patches to your clothes

Personal patches could reduce energy waste in buildings, Rutgers-led study says

What if, instead of turning up the thermostat, you could warm up with high-tech, flexible patches sewn into your clothes - while significantly reducing your...

Im Focus: Lethal combination: Drug cocktail turns off the juice to cancer cells

A widely used diabetes medication combined with an antihypertensive drug specifically inhibits tumor growth – this was discovered by researchers from the University of Basel’s Biozentrum two years ago. In a follow-up study, recently published in “Cell Reports”, the scientists report that this drug cocktail induces cancer cell death by switching off their energy supply.

The widely used anti-diabetes drug metformin not only reduces blood sugar but also has an anti-cancer effect. However, the metformin dose commonly used in the...

Im Focus: New Foldable Drone Flies through Narrow Holes in Rescue Missions

A research team from the University of Zurich has developed a new drone that can retract its propeller arms in flight and make itself small to fit through narrow gaps and holes. This is particularly useful when searching for victims of natural disasters.

Inspecting a damaged building after an earthquake or during a fire is exactly the kind of job that human rescuers would like drones to do for them. A flying...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

ICTM Conference 2019: Digitization emerges as an engineering trend for turbomachinery construction

12.12.2018 | Event News

New Plastics Economy Investor Forum - Meeting Point for Innovations

10.12.2018 | Event News

EGU 2019 meeting: Media registration now open

06.12.2018 | Event News

 
Latest News

Pressure tuned magnetism paves the way for novel electronic devices

18.12.2018 | Materials Sciences

New type of low-energy nanolaser that shines in all directions

18.12.2018 | Physics and Astronomy

NASA research reveals Saturn is losing its rings at 'worst-case-scenario' rate

18.12.2018 | Physics and Astronomy

VideoLinks
Science & Research
Overview of more VideoLinks >>>